TYK Medicines, Inc
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO0%
Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open TYK Medicines, Inc on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TY-9591 NCT05382728 |
P3 | Recruiting | NSCLC; EGFR Activating Mutation | 680 | 2025-05 |
| TY-9591 NCT05948813 |
P2 | Recruiting | NSCLC; EGFR Activating Mutation | 420 | 2025-12-15 (+6 mo) |
| TYK-00540 NCT06950086 |
P1/2 | Recruiting | HR-positive, HER2-negative Advanced Breast Cancer | 180 | 2026-09 |
| TY-302 NCT07104617 |
P1/2 | Not yet recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 48 | 2026-10 |
| TYK-00540 NCT07104643 |
P1/2 | Not yet recruiting | mCRPC | 48 | 2026-11 |
| TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin NCT06672068 |
P2 | Not yet recruiting | NSCLC | 60 | 2027-12-01 |
| TYK-01054 NCT07282873 |
P1/2 | Not yet recruiting | Solid Tumor Malignancies; Malignant Mesothelioma (MM) | 219 | 2028-01 |